I am a science and technology journalist who writes about how biology is shaping our future. Currently, I am a staff writer at OneZero and an adjunct instructor in the graduate science writing program at Johns Hopkins. I write often about CRISPR, genetic privacy, reproductive technology, neuroscience, anti-aging, and lately, Covid-19. In my work, I seek to illuminate the both the tremendous benefits and unintended consequences of biomedical advances. ​ 

 

Previously, I served as the associate editor for biomedicine at MIT Technology Review. ​There, my enterprise reporting uncovered original stories about a fertility startup advertising an unproven "three-person" IVF technique, a dubious CRISPR trial in Mexico to treat lung cancer patients, and the first commercial use of a landmark gene therapy a year after its approval. While at Tech Review, I won a Newsbrief Award from the D.C. Science Writers Association for my story about a menstrual cycle-on-a-chip.

​My stories have been published by The Washington Post, New York Times, Wall Street Journal, Scientific American, National Geographic, The Atlantic, Science, Quartz, Pacific Standard, and The Baltimore Sun, among others.  

 

I started my career as a reporter at the Baltimore Business Journal, where I followed the high-profile case of a Maryland cardiologist accused of implanting unnecessary heart stents in patients. I earned my bachelor's degree in journalism at Ohio University and a master's in science writing from Johns Hopkins. I hail from the scenic Laurel Highlands of Western Pennsylvania and now live in Baltimore, Maryland.

 

© 2020 Emily Mullin

  • Grey Twitter Icon
  • Grey LinkedIn Icon